Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FDA Adverse Event Reporting System (FAERS)
HER2-positive breast cancer patients receiving T-DCs require additional cardiac monitoring, particularly for stroke in younger patients.
Authors
- Yezhi Guan (ORCID: https://orcid.org/0000-0003-0975-6042)
- Huanhuan Jia (ORCID: https://orcid.org/0000-0003-4151-0915)
- Nvlue Cai
- Runlong Hu
- Jinfang Hu (ORCID: https://orcid.org/0000-0002-8563-8278)
- Siyu Chen (ORCID: https://orcid.org/0000-0003-0680-3894)
- Xi Chen (ORCID: https://orcid.org/0000-0001-9138-1432)
Institutions
- Shenyang Ligong University (CN)
- Guangdong Laboratory Animals Monitoring Institute (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1080/14740338.2024.2442513
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Guangdong Province